Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis
- PMID: 21708792
- DOI: 10.1093/eurpub/ckr083
Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis
Abstract
Background: Previous evidence synthesis estimates of Hepatitis C Virus (HCV) in England did not consider excess HCV risk in ethnic minority populations. We incorporate new information on HCV risk among non-injectors by ethnic group, and additional information on injecting prevalence in order to generate new and updated estimates of HCV prevalence risk in England for 2005.
Methods: Bayesian evidence synthesis was used to combine multiple sources of data that directly or indirectly provide information on the populations at risk, or prevalence of HCV infection. HCV data were modelled by region, age group and sex as well as ethnicity for never-injectors and by injecting status (ex and current).
Results: Overall HCV antibody prevalence in England was estimated at 0.67% [95% credible interval (95% CrI): 0.50-0.94] of those aged 15-59 years, or 203 000 (153 000, 286 000) individuals. HCV prevalence in never-injectors remains low, even after accounting for ethnicity, with a prevalence of 0.05% (95% CrI 0.03-0.10) in those of white/other ethnicity and 0.76% (0.48-1.23) in South Asians. Estimates are similar to 2003, although patterns of injecting drug use are different, with an older population of current injecting drug users and lower estimated numbers of ex-injectors, but higher HCV prevalence.
Conclusions: Incorporating updated information, including data on ethnicity and improved data on injectors, gave similar overall estimates of HCV prevalence in England. Further information on HCV in South Asians and natural history of injecting are required to reduce uncertainty of estimates. This method may be applied to other countries and settings.
Similar articles
-
Hepatitis C infection among injecting drug users in England and Wales (1992-2006): there and back again?Am J Epidemiol. 2009 Aug 1;170(3):352-60. doi: 10.1093/aje/kwp141. Epub 2009 Jun 22. Am J Epidemiol. 2009. PMID: 19546152 Free PMC article.
-
Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 2: Preliminary UK estimates of prevalent injection-related hepatitis C carriers, and derivation of progression rates to liver cirrhosis by gender and age at hepatitis C virus infection.J Epidemiol Biostat. 2001;6(3):267-77; discussion 279-85. J Epidemiol Biostat. 2001. PMID: 11437089
-
Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 1: Critical hepatitis C and injector data.J Epidemiol Biostat. 2001;6(3):243-65; discussion 279-85. J Epidemiol Biostat. 2001. PMID: 11437088
-
HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection.Int J Drug Policy. 2007 Oct;18(5):341-51. doi: 10.1016/j.drugpo.2007.01.016. Epub 2007 May 2. Int J Drug Policy. 2007. PMID: 17854721 Review.
-
Hepatitis C virus infection in Scotland: epidemiological review and public health challenges.Scott Med J. 2006 May;51(2):8-15. doi: 10.1258/RSMSMJ.51.2.8. Scott Med J. 2006. PMID: 16722130 Review.
Cited by
-
Estimating the number of people with hepatitis C virus who have ever injected drugs and have yet to be diagnosed: an evidence synthesis approach for Scotland.Addiction. 2015 Aug;110(8):1287-300. doi: 10.1111/add.12948. Epub 2015 Jun 8. Addiction. 2015. PMID: 25876667 Free PMC article.
-
Monitoring the hepatitis C epidemic in England and evaluating intervention scale-up using routinely collected data.J Viral Hepat. 2019 May;26(5):541-551. doi: 10.1111/jvh.13063. Epub 2019 Feb 28. J Viral Hepat. 2019. PMID: 30663179 Free PMC article.
-
The role of circulatory systemic environment in predicting interferon-alpha-induced depression: The neurogenic process as a potential mechanism.Brain Behav Immun. 2019 Oct;81:220-227. doi: 10.1016/j.bbi.2019.06.018. Epub 2019 Jun 14. Brain Behav Immun. 2019. PMID: 31207337 Free PMC article.
-
Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection.Hepatology. 2014 Apr;59(4):1343-50. doi: 10.1002/hep.26926. Epub 2014 Feb 28. Hepatology. 2014. PMID: 24214920 Free PMC article.
-
Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis.Hepatology. 2016 Jun;63(6):1796-808. doi: 10.1002/hep.28497. Epub 2016 Mar 22. Hepatology. 2016. PMID: 26864802 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical